kybella before and after, a non-surgical injectable treatment for submental fullness, was approved by the FDA in 2015. Prior to its approval, deoxycholic acid, the active ingredient in Kybella, was used in the treatment of gallbladder stones.
Research and Development:
- Early Studies: Initial research on deoxycholic acid focused on its ability to dissolve gallstones.
- Submental Fullness: Scientists later discovered that deoxycholic acid could also effectively target and destroy fat cells.
- Clinical Trials: Rigorous clinical trials were conducted to assess the safety and efficacy of Kybella for submental fullness.
FDA Approval:
- 2015 Approval: After successful clinical trials, Kybella was approved by the FDA in 2015 for the improvement of submental fullness.
- First FDA-Approved Treatment: Kybella became the first and only FDA-approved non-surgical treatment for this condition.
Growing Popularity:
Since its approval, Kybella has gained significant popularity as a safe and effective alternative to surgical procedures for addressing a double chin. Its minimal downtime, natural-looking results, and non-surgical approach have contributed to its widespread use.
Conclusion:
Kybella’s journey from a treatment for gallstones to a popular option for submental fullness demonstrates the versatility of medical research. Its FDA approval and subsequent popularity have solidified its position as a valuable tool in the field of aesthetic medicine.
